Prinaberel

In this article, we will explore the topic of Prinaberel in depth. Throughout history, Prinaberel has played a crucial role in various areas of society, from culture and art to science and technology. Through a detailed analysis, we will analyze the importance of Prinaberel in the contemporary context, as well as its influence on the development and evolution of different aspects of daily life. Additionally, we will examine how Prinaberel has been subject to multiple interpretations and approaches over time, which has contributed to its continued relevance today. From its origins to its presence today, Prinaberel has left an indelible mark on the world, and this article seeks to examine and understand its impact in depth.

Prinaberel
Clinical data
ATC code
  • None
Identifiers
  • (4Z)-2-Fluoro-4-(5-hydroxy-7-vinyl-1,3-benzoxazol-2(3H)-ylidene)-2,5-cyclohexadien-1-one
CAS Number
PubChem CID
ChemSpider
UNII
ECHA InfoCard100.222.969 Edit this at Wikidata
Chemical and physical data
FormulaC15H10FNO3
Molar mass271.247 g·mol−1
3D model (JSmol)
  • O=C3\C=C/C(=C2/Oc1c(cc(O)cc1N2)\C=C)/C=C3/F
  • InChI=1S/C15H10FNO3/c1-2-8-5-10(18)7-12-14(8)20-15(17-12)9-3-4-13(19)11(16)6-9/h2-7,17-18H,1H2/b15-9-
  • Key:FCXYSEXZEGPLGG-DHDCSXOGSA-N

Prinaberel (INN, USAN) (developmental code names ERB-041, WAY-202041) is a synthetic, nonsteroidal, and highly selective agonist of the ERβ subtype of the estrogen receptor. It is used in scientific research to elucidate the role of the ERβ receptor. Studies have indicated that selective ERβ agonists like prinaberel could be useful in the clinical treatment of a variety of medical conditions including inflammatory bowel disease, rheumatoid arthritis, endometriosis, and sepsis. Accordingly, prinaberel either was or still is under investigation by Wyeth for the treatment of some of these conditions.

See also

References

  1. ^ Harris HA, Albert LM, Leathurby Y, et al. (October 2003). "Evaluation of an estrogen receptor-beta agonist in animal models of human disease". Endocrinology. 144 (10): 4241–9. doi:10.1210/en.2003-0550. PMID 14500559.
  2. ^ Koehler KF, Helguero LA, Haldosén LA, Warner M, Gustafsson JA (May 2005). "Reflections on the discovery and significance of estrogen receptor beta". Endocrine Reviews. 26 (3): 465–78. doi:10.1210/er.2004-0027. PMID 15857973.
  3. ^ Harris HA (2006). "Preclinical characterization of selective estrogen receptor beta agonists: new insights into their therapeutic potential". Ernst Schering Foundation Symposium Proceedings. 2006/1 (1): 149–61. doi:10.1007/2789_2006_021. ISBN 978-3-540-49547-5. PMID 17824176.
  4. ^ "Prinaberel - Wyeth phase change II, USA (endometriosis)". R & D Focus Drug News. 2006-06-05. Archived from the original on 2016-03-07. Retrieved 2012-05-20.

External links



Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia